argenx SE (NASDAQ:ARGX) Position Boosted by Ballentine Partners LLC

Ballentine Partners LLC increased its holdings in argenx SE (NASDAQ:ARGX) by 21.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 536 shares of the company’s stock after purchasing an additional 95 shares during the quarter. Ballentine Partners LLC’s holdings in argenx were worth $330,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ARGX. Stifel Financial Corp increased its holdings in shares of argenx by 15.3% in the third quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock valued at $4,788,000 after buying an additional 1,170 shares in the last quarter. FMR LLC raised its position in shares of argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after purchasing an additional 1,265,486 shares during the period. Simplify Asset Management Inc. lifted its holdings in shares of argenx by 64.0% during the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock valued at $1,311,000 after purchasing an additional 944 shares during the last quarter. Perpetual Ltd purchased a new stake in shares of argenx during the third quarter valued at $76,314,000. Finally, Westfield Capital Management Co. LP acquired a new position in shares of argenx in the 3rd quarter valued at $571,000. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Stock Down 0.5 %

Shares of ARGX opened at $648.94 on Friday. The firm has a market cap of $39.18 billion, a price-to-earnings ratio of -737.43 and a beta of 0.59. The company’s fifty day moving average is $625.94 and its 200-day moving average is $562.96. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. During the same period in the prior year, the business posted ($1.25) earnings per share. As a group, research analysts predict that argenx SE will post 2.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on ARGX shares. JPMorgan Chase & Co. upped their price objective on shares of argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. HC Wainwright restated a “buy” rating and issued a $717.00 price target (up previously from $670.00) on shares of argenx in a research report on Tuesday, January 14th. Truist Financial reiterated a “buy” rating and set a $700.00 price objective (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Piper Sandler lifted their price target on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.